Centre for Targeted Protein Degradation
The Centre for Targeted Protein Degradation (CeTPD) is bolstering the University of Dundee’s world-leading position in a field that is revolutionising drug discovery.
Targeted protein degradation
Targeted protein degradation co-opts the cell’s natural disposal systems to remove disease-causing proteins and is applicable to diverse therapeutic areas including oncology, dermatology, immunology, neuroscience and respiratory diseases.
This entirely new approach is revolutionising drug discovery by making the treatment of diseases previously thought to be undruggable a reality.
CeTPD is part of the University’s School of Life Sciences, one of the UK’s top institutions for research into biological sciences.
Dundee researchers and teams led by Professor Alessio Ciulli have previously revealed fundamental insights into the working of the degrader molecules that they have designed and that are used across the globe. Collaborations with pharma companies Boehringer Ingelheim and Almirall amongst others are helping to advance the field, while the biopharmaceutical company Amphista Therapeutics is a University of Dundee spin-out of the Ciulli Lab.
Our new translational research centre will build on this established excellence to innovate groundbreaking science and accelerate translation by developing and inspiring the next generation of scientists and leaders.
Professor Alessio Ciulli
A one day symposium for the Scottish cryo-EM community took place on 30 November 2023
The commercial achievements of a University of Dundee spinout have been recognised with a top prize at a major awards ceremony.
University of Dundee researchers have developed a new molecule that is able to target and bind to a protein class previously considered undruggable by using a masking technique to enter the cell
A University of Dundee research centre at the heart of a revolution in drug discovery has been officially opened by the UK’s Science Minister.
A prestigious audience of policy makers, entrepreneurs and scientists from across the UK will hear about Dundee’s world-leading expertise in drug discovery at next month’s Braemar Summit.
CeTPD Outreach is a public engagement sub-team branching in the new Centre for Targeted Protein Degradation as part of the University’s School of Life Sciences.
Dr Will Farnaby, Principal Investigator in the Centre for Targeted Protein Degradation (CeTPD), has been awarded a Wellcome Trust Early Career Award.
University of Dundee spinout Amphista Therapeutics today announced the delivery of the first discovery milestone under a collaboration and licence agreement with global biopharmaceutical company Bristol Myers Squibb.